Purpose Aberrant DNA methylation occurs frequently in breast carcinogenesis. Tools for translational epigenetic studies of breast cancer involving formalin-fixed paraffinembedded (FFPE) human tissues have now been developed. Few studies have measured genome-wide methylation in DNA derived from paraffin-embedded tumour tissues and compared the DNA methylation in corresponding adjacent non-tumour ductal epithelium (ADJ NT ). These studies are technically challenging due to the spectrum of breast cancer pathologies, the variable suitability of DNA extracted from FFPE material and the difficulties in identifying ADJ NT . We assessed the suitability of FFPE breast cancer material for genome-wide DNA methylation assessment of tumour and ADJ NT .
Introduction DNA methylation plays a critical role in cancer. Virtually all tumour cells feature genomic instability induced through global loss of DNA methylation and transcriptional silencing of tumour suppressor genes from promoter hypermethylation [1] . DNA methylation aberrations at several tumour suppressor genes have been measured in breast tumours and some of these methylation marks may explain specific clinicopathological characteristics [2] . Importantly, DNA methylation profiles may enable stratification over and beyond gene expression data. DNA methylation is more stable than gene transcripts and therefore more feasible for clinical use. For example, Dedeurwaerder et al. [3] have identified novel DNA methylation profiles that suggest existence of additional breast cancer subtypes above those classified by current expression subtypes [3] . Recent data from TCGA have dramatically expanded the number of genes identified as aberrantly methylated in breast cancers, and several studies have found that DNA methylation might be responsible for at least some of the observed tumour heterogeneity [4, 5] . Further, DNA methylation marks are dynamic and change throughout tumour progression [2] . van Hoesel et al. (2013) reported DNA hypermethylation of selected genes such as RASSF1A and RARß2 occur early in breast carcinogenesis, suggesting the potential of their use as biomarkers for early detection [6] . Taken together, the potential for DNA methylation marks to be utilised as diagnostic and therapeutic targets in breast cancer is well established.
Recent advances in technology have enabled research in this area to expand from single or few molecularly targeted assays to platforms that conduct genome-wide assessment of the methylome. The capacity of these platforms to scan the genome in one assay and their demonstrated utility for the analysis of FFPE material offer great promise to further refine our understanding of DNA methylation in cancer, including its role in neoplastic change and tumorigenic pathways of cancer progression [7] . Fulfilling this promise could enable the resources of large epidemiological studies, that commonly collect and store diagnostic FFPE material, to underpin ongoing research, identify new diagnostic and therapeutic agents and provide the evidence base for translation.
For some research questions, there is great importance and reliance on assessing methylation in both tumour and adjacent non-tumour ductal epithelium (ADJ NT ) to identify alterations in the tumourigenic process. The utility of this approach has been demonstrated by several studies that have primarily used loci-specific assessment of DNA extracted from fresh frozen material [8] [9] [10] [11] . For example, Bardowell et al. [8] assessed the methylation levels of 70 candidate genes (across 1200 CpG dinucleotides) in fresh frozen tumour and matched ADJ NT and identified six distinct methylation patterns in these breast tumours, with some displaying correlated methylation and gene expression patterns. Li and colleagues measured DNA methylation in 48 genes from 150 paired fresh frozen breast tumour and ADJ NT and reported a methylation pattern which could be used to predict the onset of breast cancer with specific clinicopathological features. Using pyrosequencing technology, Rauscher et al. [10] showed that large field effects were present in breast cancer when they pyrosequenced 16 gene loci in more than 100 FFPE breast tumours, ADJ NT and unaffected control reduction mammoplasty samples. This observation was confirmed by the most comprehensive study of this type to date by Teschendorff et al. [11] who measured genome-wide methylation using the Infinium HumanMethylation450 Beadchip (HM450K) array from DNA extracted from snap-frozen breast cancer tissues, normal/benign tissues and matched breast and ADJ NT (total n = 569).
Selecting tissue for analysis is challenging as it is complicated by several aspects related to the histological variation of breast cancers that result in the following: (i) tumour-enriched DNA samples being prepared for analysis (variably contaminated with non-tumour material); (ii) contamination of ADJ NT with tumour cells; and (iii) availability (identification) of histopathologically normal tissue from the adjacent fields. Work involving the use of FFPE material offers increased capacity for precision with regards to tissue selection, but the DNA extracted from this material is a more complex template (in terms of quality) for the current, high-density molecular platforms.
In contrast to the work described above, we sought to evaluate the capacity of diagnostic FFPE material to provide DNA samples representing the tumour and ADJ NT suitable for assessment on the HM450K array. We utilised resources from the MCCS and measured genome-wide methylation in DNA extracted from 21 pairs of breast tumour and ADJ NT .
Materials and methods

Melbourne collaborative cohort study (MCCS)
The MCCS is a prospective study of more than 40,000 men and women who were recruited in the years 1990-1994 [12] . The vast majority of participants ([99 %) were aged 40-69 at recruitment (baseline), when a wide range of epidemiological data as well as blood samples and physical measurements were collected from the participants. Pathological materials related to breast cancers diagnosed in female participants were retrieved from the diagnostic service laboratory and reviewed by qualified pathologists. Representative haematoxylin and eosin (H&E)-stained sections and unstained Sections. (3 lm) were prepared and stored desiccated for up to 15 years at 4°C. Immunohistochemical staining and breast cancer subtyping were conducted as described by Blows et al. [13] . Written informed consent was obtained from each participant, and the study was approved by the Human Research Ethics Committee of Cancer Council Victoria.
DNA extraction from FFPE breast tumour and ADJ NT tissues
DNA was extracted as previously described from FFPE breast tumour and ADJ NT material that had been fixed in separate tissue blocks [7] . Briefly, the tumour area and the ADJ NT tissue for 21 individuals (42 FFPE tissue samples in total) most suitable for macrodissection were identified by a single pathologist (CAM) using the WHO Classification of Tumours of the Breast criteria [14] . FFPE tissue was macrodissected from at least two 3 lm methyl greenstained sections using a 21-guage needle followed by protease digestion using Proteinase K for 48 h. Macrodissection for all FFPE tissue samples was performed on the same day by the same scientist (EMW) to reduce potential batch effects. DNA was extracted using the QIAamp DNA FFPE tissue kit (Qiagen, Hilden, Germany) as per manufacturer's protocol except that DNA was eluted twice to obtain a final volume of 25 ll and stored at 4°C.
Sodium bisulfite conversion
Sodium bisulfite conversion was performed using the EZ DNA Methylation-Gold kit (Zymo, Irvine, CA, USA). FFPE-derived DNA was bisulfite converted (24-750 ng input DNA) and eluted in a final volume of 8 ll elution buffer. Bisulfite-converted DNA was stored long term at -20°C.
Quality control (QC) assessments
The following QC assessments were applied to extracted FFPE DNA samples prior to the application on the HM450K array: (1) QC1: confirm the availability of DNA after extraction using the Qubit dsDNA BR assay (Life Technologies, Carlsbad, CA, USA); (2) QC2: evaluate the quality of archival tissue DNA using the Infinium HD FFPE QC assay (Illumina, San Diego, CA, USA); and (3) QC3: confirm the availability of DNA after sodium bisulfite conversion and FFPE restoration using an in-house bisulfite-specific qPCR assay [7] .
Infinium HumanMethylation450 beadchip (HM450K) assay
The HM450K assay (Illumina, San Diego, CA, USA) was performed as per manufacturer's instructions. One FFPE tumour and ADJ NT DNA pair was run as replicates to ensure the reproducibility of data, and one high molecular weight DNA extracted from a U266 multiple myeloma cell line was included to further control the assay.
Data processing and statistical analysis
Raw data were imported into R environment, normalised and processed using the minfi package, as previously described [15, 16] . HM450K probes or individual samples that did not meet the following criteria were removed from further analysis: (1) average detection p-value across all probes/sample B0.01 and (2) individual probe detection pvalue of B0.05. b and M-values were calculated from 480, 136 CpG probes in 36 samples. Three-dimensional principal component analysis (3D-PCA) plots were generated using the scatterplot3d R package. Differentially methylated probes were identified using the limma Bioconductor package [17] , taking the pairwise design into account. All graphics were generated using ggplot2 unless stated otherwise.
Analysis of TCGA data
The HM450K data of matched tumour and ADJ NT ([2 cm from tumour) from 90 women were downloaded from the National Cancer Institute webpage (https://tcga-data.nci. nih.gov/tcga/tcgaDownload.jsp). The data were background corrected and normalised according to the Illumina and Subset-quantile Within Array Normalisation (SWAN) methods [18] . The clinical information was also downloaded from the NCI website.
Comparison with other tumour-ADJ NT studies
To test for the age-associated methylation in normal breast tissue as reported by Johnson et al. [19] , linear regression was performed using M-values from the 18 ADJ NT and patient age, which ranged from 51.7 to 77.6 years [17] . Differentially Methylated Regions (DMRs) were identified between the 18 tumour and ADJ NT pairs using the DMRcate R package [20] and individually compared with the 37 differentially methylated gene promoters reported by Li et al. [9] .
Results
Histological examination of the FFPE breast material collected from 21 breast cancer cases participating in the MCCS identified tumour-enriched and ADJ NT areas for macrodissection. The ADJ NT areas included nine cases with histologically normal duct epithelium (N), six cases with atrophic duct tissue and three cases with fibrocystic disease (FCD) ( Table 1 ). The estimated percentage of normal ductal epithelium on a background of stroma and adipose components ranged from 3 to 10 %. The tumours comprised [99.5 % infiltrating tumour in all cases. Ductal carcinoma in situ constituted \0.5 % of macrodissected material.
The amount of DNA extracted from these 42 tumour and ADJ NT FFPE tissue samples (21 pairs) ranged from 24 ng to 1.5 ug. Due to insufficient DNA, one ADJ NT sample and its matched tumour DNA were not progressed further. The remaining 40 tumour and ADJ NT DNAs passed the Infinium HD QC assay threshold cutoff of DCq B 6. After sodium bisulfite conversion and FFPE restoration, two ADJ NT DNAs did not meet the final bisulfite-specific qPCR threshold cutoff (DCq C 4) and together with their matched tumour DNA were not assayed on the HM450K array [7] . A total of 36 FFPE tumour and ADJ NT DNAs from 18 individuals remained for genome-wide methylation profiling on the HM450K array.
Genome-wide methylation profiles
After removing probes that did not pass the HM450K data quality criteria, 480, 136 Infinium probes (98.9 %) remained for further analysis. Three-dimensional PCA was performed to illustrate overall similarities based on DNA methylation levels detected by all remaining CpG probes. Figure 1 shows the relationship between all tumour and ADJ NT samples and also the relationship between each tumour and its matching ADJ NT sample from each of the 18 women. Supplementary Fig. 1 shows the scatterplots between all 18 tumour and ADJ NT pairs and their respective correlation coefficients. Figure 2 further illustrates sample 3 (R = 0.984) and sample 7 (R = 0.853).
Comparison of FFPE genome-wide methylation with TCGA
We compared the FFPE HM450K dataset with the publicly available TCGA HM450K dataset. A total of 105, 545 marks were differentially methylated (FDR adj pvalue B0.01) between the archival FFPE tumour and ADJ NT DNAs. Of these, 101, 672 ([96 %) marks were also differentially methylated in the TCGA dataset (data not shown). To test whether the methylation status of DMPs identified from this FFPE dataset could also separate tumour samples from matched ADJ NT in TCGA dataset (generated from fresh frozen material), we plotted a methylation heatmap using the 1000 most significantly DMPs identified in the FFPE dataset. We found that the DMPs were effective for differentiating tumour and ADJ NT within the TCGA dataset (Fig. 3) .
We further compared the DNA methylation levels between the FFPE-derived samples and fresh frozen samples from TCGA in selected genes. The RAS association domain family protein 1A (RASSF1A) and high in normal-1 (HIN-1) genes were assessed as these tumour suppressor genes have been shown to often be deregulated through methylation aberration in breast cancer. The NK6 Homeobox 2 (NKX6-2) gene was assessed as it was identified to be one of most significant differentially methylated regions (clusters of CpG sites) in the FFPE-derived samples. For all three genes, methylation profiles observed in both the FFPE and TCGA datasets were highly correlated ( Supplementary Fig. 2 ).
Comparison of FFPE genome-wide methylation with other tumour-ADJ NT studies
Johnson et al. reported that 24 HM27K probes with agerelated methylation in normal breast tissue were also significantly differentially methylated between normal and breast tumour tissues [19] . While the cg15465321 probe was not available in the HM450K array, the FFPE data demonstrated statistically significant (FDR adj. pvalue \0.05) differential methylation at 17 of the remaining 23 probes reported by Johnson et al. (Supplementary  Fig. 3 ). Although we did not identify any significant probes associated with age in the ADJ NT , this was likely to be due to the lack of power.
Using microfluidic PCR-based target enrichment and next-generation bisulfite sequencing technology, Li et al. [9] analysed methylation status of 48 candidate genes in paired tumour and normal tissues from 180 Chinese breast cancer patients [9] . The promoter regions of 31 of the 37 genes reported by Li et al. were also differentially methylated in the FFPE-derived dataset ( Supplementary   Fig. 1 Genome-wide DNA methylation profiles of tumour DNA (black) and ADJ NT (green) samples presented as a 3D-PCA plot. Tumour and ADJ NT samples are numbered as per Table 1 . Dotted lines connect each matched tumour and ADJ NT pair Table 1 ). Interestingly, SOX17 that had been identified as one of the most significant candidate biomarkers for cancer prediction had one of the smallest Stouffer-transformed FDR-adjusted p-value in the FFPE dataset (FDR adj. pvalue = 4.17 9 10 -39 ).
Discussion
There is an increasing need to conduct large-scale studies examining genome-wide DNA methylation of FFPE breast cancer specimens as it offers opportunities to increase histological precision, to study subtypes that are underrepresented in the TCGA data and to provide capacity to further explore intra-tumoural heterogeneity. This report demonstrates the potential of FFPE material to be used in this setting. Although TCGA has comprehensive and systematic analyses of molecular changes such as DNA methylation for 707 breast tumours [4] , there are several limitations for its clinical use: (1) there is missing molecular subtype information on 37 % of TCGA breast cancer cases; (2) family history was not collected in TCGA, and there is incomplete clinical information on many of the cases making it impossible to stratify the results for clinical counselling based on underlying risk of breast cancer; and (3) only 13 % of samples have methylation profiles in the corresponding non-tumour tissues. As the epigenomes vary according to characteristics of the study sample including the distribution of age, race/ethnicity and underlying risk, it is essential to select a well-characterized sample for the identification of markers, so that the results will be useful for its integration into clinical care [21] . Thus, it is critical to know how viable FFPE methods are when applying them to large epidemiologic cohorts. The comparison of this FFPE DNA-derived HM450K data with TCGA HM450K data demonstrated consistencies between the two datasets despite the differences in sample size and DNA source. By applying the 1000 most DMPs in the FFPE dataset to TCGA data from fresh frozen material, we found that the same DMPs were able to differentiate ADJ NT from tumour tissue in TCGA dataset (Fig. 3) . Further demonstration of the reliability of the FFPE methylation data was achieved by comparison of the data with the studies of Johnson et al. [19] and Li et al. [9, 19] .
We additionally performed a simple methylation assessment of several genes widely reported to be aberrantly methylated in cancer. Both RASSF1A and HIN-1 are tumour suppressor genes that are frequently methylated in breast cancer [22] [23] [24] . In RASSF1A, only one of the two CpG islands in the promoter region is methylated in breast cancer tissue [24, 25] . Evaluation of the Infinium probes across the RASSF1A promoter confirmed that the probes overlapping this CpG island (chromosome 3: 50,377,815-50,378,540) had high levels of methylation in the FFPE-derived breast tumours (Supplementary Fig. 2) . Evaluation of the FFPE data found the NKX6-2 gene to be differentially methylated in tumour compared to ADJ NT across all probes specific to the gene (individual probe Db = 0.02-0.45). NKX6-2 is a homeobox gene that has previously been demonstrated to be methylated in renal cell and bladder cancer [21, 26] . Methylation of this gene in breast cancer has not been reported previously.
This work provides evidence that the resources of large collections of FFPE material could be used in studies examining the role of methylation in breast cancer tumourigenesis. This could allow epidemiological studies to underpin ongoing research aiming to identify new diagnostic markers and therapeutic agents and at the same time provide the evidence base for translation of such information.
